drugset / Trial / NCT05385978
A Study of Distal Jejunal-release Dextrose in Obese Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in obese participants.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2024-11-11
- Completion
- 2024-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | APHD-012 | Unknown | 12 g | — |